Analyst Reiterates Buy on Dianthus as Claseprubart Data Momentum and New Pipeline Assets Strengthen Risk-Reward Profile
Tip Ranks·- William Blair analyst Myles Minter reaffirmed a buy rating on Dianthus on September 11, citing strong momentum and an improved risk-reward profile. - The optimism is driven by the fully enrolled Phase 2 MoMeNtum trial for claseprubart in multifocal motor neuropathy, with data expected in December, alongside promising interim efficacy in the CAPTIVATE study. - Additional financial institutions like JPMorgan also initiated coverage with a buy rating and a target price of $ 135.00 .